Octreotide Long-Acting Repeatable for the Treatment of Chronic Macular Edema in Uveitis

American Journal of Ophthalmology

Volumn 144, Issue 6, 2007, Pages

  Missotten, Tom ^a   van Laar, Jan A M ^b   van der Loos, Theo L ^a   van Daele, Paul L A ^c   Kuijpers, Robert W A M ^b   Baarsma, G Seerp ^a   van Hagen, P Martin ^b  

^a ROTTERDAM EYE HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; STEROID;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; RETINA MACULA EDEMA; UVEITIS; VISUAL ACUITY;

EID: 36249031650     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.07.039     Document Type: Article

References (48)

1. Lardenoye C.W., van Kooij B., and Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 113 (2006) 1446-1449
2. Tranos P.G., Wickremasinghe S.S., Stangos N.T., Topouzis F., Tsinopoulos I., and Pavesio C.E. Macular edema. Surv Ophthalmol 49 (2004) 470-490
3. Okhravi N., and Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm 11 (2003) 29-38
4. van Kooij B., Rothova A., and de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm 14 (2006) 73-85
5. Angunawela R.I., Heatley C.J., Williamson T.H., et al. Intravitreal triamcinolone acetonide for refractory uveitic cystoid macular edema: long-term management and outcome. Acta Ophthalmol Scand 83 (2005) 595-599
6. Kok H., Lau C., Maycock N., McCluskey P., and Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112 (2005) 1916
7. Schilling H., Heiligenhaus A., Laube T., Bornfeld N., and Jurklies B. Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 25 (2005) 182-188
8. Zierhut M., Thiel H.J., and Schlote T. Treatment of uveitic macular edema with acetazolamide. Doc Ophthalmol 97 (1999) 409-413
9. Whitcup S.M., Csaky K.G., Podgor M.J., Chew E.Y., Perry C.H., and Nussenblatt R.B. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 103 (1996) 1054-1062
10. Boehm B.O. Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract Res Clin Gastroenterol 16 (2002) 493-509
11. In: Lamberts S.W.J., and Ghigo E. (Eds). The expanding role of Octreotide II: advances in endocrinology and eye diseases (2002), Bioscientifica, Ltd, Bristol, United Kingdom 165-184
12. Lichtenauer-Kagilis E.G.R., van Hagen P.M., Lamberts S.W.J., and Holland L.J. Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol 143 (2000) S21-S25
13. Oomen S.P.M.A., Hofland L.J., van Hagen P.M., Lamberts S.W.J., and Touw I.P. Somatostatin receptors in the hematopoietic system. Eur J Endocrinol 143 (2000) S9-S14
14. Zavros Y., Kao J.Y., and Merchant J.L. Inflammation and Cancer III. Somatostatin and the innate immune system. AJP (GI) 286 (2004) 698-701
15. Weinstock J.V., and Elliott D. The somatostatin immunoregulatory circuit present at sites of chronic inflammation. Eur J Endocrinol 143 (2000) S15-S19
16. Ferone D., van Hagen P.M., Semino C., et al. Somatostatin receptor distribution and function in immune system. Dig Liver Dis 36 (2004) S68-S77
17. Wegewitz U., Goehring I., and Spranger J. Novel approaches in the treatment of angiogenic eye disease. Curr Pharmaceut Design 11 (2005) 2311-2330
18. Grant M.B., and Caballero S. Somatostatin analogues as drug therapies for retinopathies. Drugs Today (Barc.) 38 (2002) 783-791
19. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102 (2004) 61-85
20. Wu P.C., Liu C.C., Chen C.H., et al. Inhibition of experimental angiogenesis of cornea by somatostatin. Graefes Arch Clin Exp Ophthalmol 241 (2003) 63-69
21. Demir T., Celiker U.O., Kukner A., Mogulkoc R., Celebi S., and Celiker H. Effect of octreotide on experimental corneal neovascularization. Acta Ophthalmol Scand 77 (1999) 386-390
22. Florio T., Morini M., Villa V., et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3 mediated regulation of endothelial nitric oxide synthase and mitogen activated protein kinase activities. Endocrinology 144 (2003) 1574-1584
23. Celiker U., and Ilhan N. Nitric oxide and octreotide in retinal ischemia-reperfusion injury. Doc Ophthalmol 105 (2002) 327-338
24. Klisovic D.D., O'Dorisio M.S., Katz S.E., et al. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest Ophthalmol Vis Sci 42 (2001) 2193-2201
25. Taylor A.W., and Yee D.G. Somatostatin is an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 44 (2003) 2644-2649
26. Mori M., Aihara M., and Shimizu T. Differential expression of somatostatin receptors in the rat eye: SSTR4 is intensely expressed in the iris/ciliary body. Neurosci Lett 223 (1997) 185-188
27. Elbadri A.A., Shaw C., Johnston C.F., Archer D.B., and Buchanan K.D. The distribution of neuropeptides in the ocular tissues of several mammals: a comparative study. Comp Biochem Physiol C 100 (1991) 625-627
28. Yamada T., Marshak D., Basinger S., Walsh J., Morley J., and Stell W. Somatostatin-like immunoreactivity in the retina. Proc Natl Acad Sci U S A 77 (1980) 1691-1695
29. Cristiani R., Petrucci C., Dal Monte M., and Bagnoli P. Somatostatin (SRIF) and SRIF receptors in the mouse retina. Brain Res 936 (2002) 1-14
30. Thermos K. Functional mapping of somatostatin receptors in the retina: a review. Vis Res 43 (2003) 1805-1815
31. Van Hagen P.M., Baarsma G.S., Mooy C.M., et al. Somatotostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 143 (2000) S43-S51
32. Lambooij A.C., Kuijpers R.W., van Lichtenauer-Kaligis E.G., et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 41 (2000) 2329-2335
33. Casini G., Catalani E., Dal Monte M., and Bagnoli P. Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retinal disease. Histol Histopathol 20 (2005) 615-632
34. Missotten T., Baarsma G.S., Kuijpers R.W., et al. Somatostatin-related therapeutics in ophthalmology: a review. J Endocrinol Invest 28 (2005) 118-126
35. Hernandez C., Carrasco E., Casamitjana R., Deulofeu R., Garcia-Arumi J., and Simo R. Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care 28 (2005) 1941-1947
36. Taylor A.W. A review of the influence of aqueous humor on immunity. Ocul Imm Inflam 11 (2003) 231-241
37. Casini G., Catalani E., Dal Monte M., and Bagnoli P. Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retinal disease. Histol Histopathol 20 (2005) 615-632
38. Boehm B.O. Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract Res Clin Gastroenterol 16 (2002) 493-509
39. Kuijpers R.W., Baarsma G.S., and van Hagen P.M. Treatment of cystoid macular edema with octreotide. N Engl J Med 338 (1998) 624-626
40. Chantelau E., and Frystyk J. Progression of diabetic retinopathy during improved metabolic control may de teated with reduced insulin dosage and/or somatostatin analogue administration: A case report. Growth Hormone IGF Res 15 (2005) 130-135
41. van Hagen P.M., Kuijpers R.W., ter Averst E., Hofland L.J., and Baarsma G.S. The clinical application of somatostatin analogues in retinal diseases. In: Lamberts S.W.J., and Ghigo E. (Eds). The expanding role of Octreotide II: advances in endocrinology and eye diseases (2002), Bioscientifica, Ltd, Bristol, United Kingdom 185-191
42. Kafkala C., Choi J.Y., Choopong P., and Foster C.S. Octreotide as a treatment for uveitic cystoid macular edema. Arch Ophthalmol 124 (2006) 1353-1355
43. 2 test for data collected on eyes. Br J Ophthalmol 77 (1993) 115-117
44. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T., and Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140 (2005) 509-516
45. Bringmann A., Reichenbach A., and Wiedemann P. Pathomechanisms of cystoid macular edema. Ophthalmic Res 36 (2004) 241-249
46. Murdoch I.E., Moris S.S., and Cousens S.N. People and eyes: statistical approaches in ophthalmology. Br J Ophthalmol 82 (1998) 971-973
47. Lustig R.H., Greenway F., Velasquez-Mieyer P., et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond) 30 (2006) 331-341
48. Colao A., Pivonello R., Auriemma R.S., et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154 (2006) 467-477